Pros | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | 2/8 | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 7 Years | ||
Fund Size | 3933 Cr | 6227 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.91% | 1.03% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 43 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.94%) Divi's Laboratories Ltd (6.36%) Max Healthcare Institute Ltd Ordinary Shares (5.67%) Cipla Ltd (4.59%) Lupin Ltd (4.08%) | Sun Pharmaceuticals Industries Ltd (11.58%) Dr Reddy's Laboratories Ltd (9.1%) Divi's Laboratories Ltd (8.75%) Aurobindo Pharma Ltd (8.25%) Cipla Ltd (6.92%) | ||
No of Sectors | 3 | 3 | ||
Top 3 Sectors | Health (94.09%) Basic Materials (5.91%) Government (1.93%) | Health (97.7%) Basic Materials (1.18%) Financial Services (1.12%) | ||
Equity % | 96.36% | 97.55% | ||
Debt % | - | - | ||
P/E | 43.78 | 30.65 | ||
P/B | 6.26 | 4.17 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.62% | -1.22% | ||
3-Month Return | 0.46% | 0.46% | ||
6-Month Return | 7.21% | 11.61% | ||
1-Year Return | 5.76% | 4.91% | ||
3-Year Return | 27.39% | 29.27% | ||
5-Year Return | 21.06% | 21.64% |
Sharpe | 1.25 | 1.24 | ||
Alpha | 4.15 | 4.3 | ||
Beta | 0.84 | 0.95 | ||
Standard Deviation | 14.09 | 15.67 | ||
Information Ratio | 0.6 | 1.4 |
Description | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Tanmaya Desai | Dharmesh Kakkad,Sharmila D’mello |